Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
about
Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitisCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Updates in ANCA-associated vasculitisWhat is new in the management of rapidly progressive glomerulonephritis?Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Lung involvement in childhood onset granulomatosis with polyangiitis.Induction monotherapy with sirolimus has selected beneficial effects on glomerular and tubulointersititial injury in nephrotoxic serum nephritis.Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvementBenefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service.Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitisThe Effects of Plasma Exchange on Severe Vasculitis with Diffuse Alveolar Hemorrhage.Plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis--a 25-year perspective.Twenty-five years of European Union collaboration in ANCA-associated vasculitis research.Role of therapeutic plasmapheresis in ANCA-associated vasculitis.Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?Hurdles to the introduction of new therapies for immune-mediated kidney diseases.Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement.Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management.Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn.Rituximab in ANCA-Associated Vasculitis.Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US.ANCA-associated vasculitis with renal involvement.EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.[Therapy of ANCA-associated vasculitis with severe renal manifestation under routine conditions].Plasmapheresis therapy in ANCA-associated vasculitides: A single-center retrospective analysis of renal outcome and mortality.Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy.Clinical Trials in Vasculitis.Glomerular disease: ANCA-associated GN--to PLEX or not to PLEX?The European Vasculitis Society 2016 Meeting Report.Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis.Pro: High dose of therapeutic plasma exchange-mind the gap!Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future?Issues in trial design for ANCA-associated and large-vessel vasculitis.Pyoderma Gangrenosum-associated Granulomatosis with Polyangitis: A Case Report and Literature Review.Con: High-volume plasma exchange application in nephrology and beyond.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].
P2860
Q26751357-CDBCA468-3C9C-4463-AE50-18A7B0D508A3Q27025692-DF52DBFB-93AB-47DA-9DCD-E5856F3F02EFQ28069897-B6F70475-C1BD-48C6-8C4B-0C0F1E4BAB27Q28259540-9ABDA152-4CF6-4C9D-8F18-3E58A9A74917Q30276550-DAC4C165-A232-42B4-9EA3-C140EE52B09BQ33564565-41452B0D-5FCD-4E6F-B7DE-8F929DFB59F6Q33952749-8EA2CD2F-46A9-4823-A700-1F36FBC1C5D1Q35228543-4EA1C4F1-D670-4879-B7FB-455B064D8391Q35836369-BD531CC2-F625-4577-AC51-11A263472A68Q37093451-C3A1ED8C-3BFA-4C49-B091-10655FFCDE22Q37640836-88FA6464-9480-45D8-B5F7-36A8B8258379Q37647438-DEE76378-6BE2-4DEC-A384-2263AAE8F1A5Q38377281-CE31E2BF-7F08-4093-BC72-5F525E8A609DQ38389839-45BA3D73-1AD6-412C-8DCD-25280661C71CQ38489783-1B54308C-47F5-475E-955B-F27B1B7031BEQ38543360-50405C4C-E915-47CA-8DBB-1C608DDD1E0AQ38709517-8EAF95E2-9476-4A29-A54B-DA76ADBA67B4Q38946711-1B3D61D6-7C76-409F-B8A5-181391F101A2Q38965278-4F4F3EB1-7D5D-4388-A435-D89FC0AB4AFCQ39072021-E1954DB0-40DA-4B40-ACD7-0CEA4F57EEC1Q39088103-8E4B2042-E220-4A25-BA25-336C42236D28Q39117005-8C8B6252-639E-4AF2-9E47-3C6C58A594EAQ39215583-0D29D4F8-24B3-4F3F-9105-16C9032D1D3FQ39339897-1B043449-0918-453C-94CD-7837D0FB1A1AQ40684657-F14DF3AC-9034-4E54-8DA7-5779C584C6DEQ40867645-8EDC9925-F660-4ADF-BC3E-A1DCB7E25F82Q41099072-E3843A5F-7FB9-4BD8-9331-4BAD9658FE45Q41208157-73CFC287-19AA-4121-AEE3-AC2B6D69D437Q41476938-3CF7B644-01E5-428A-839F-B51FB78B371AQ41481664-B5151DCB-9785-4DD8-BC5A-20F966131636Q44119588-30A5FF72-5BE8-4A75-AD4E-28A5EB6110D0Q47107377-4D91B55B-61D2-4486-8BF6-B8290ED8510DQ47191744-7A053521-488A-4E88-B367-E3DE26C3D95BQ47553136-9568D67F-B74B-4810-99FF-9273A7FB1413Q47741998-549136A7-9898-4A63-9EB6-48400A5EB1FBQ47800187-F91E0ED4-7FC1-4FE8-823A-B0CA7D46DB97Q48937679-FD7BA6B4-AE7F-4865-9A04-240C93E735BBQ49679461-EDEF9F03-1DD5-420B-9B7F-D535C60FF102Q50069110-7052E3F0-60E3-458D-AEB8-CF8FB048831CQ50076914-F68FBFE5-231F-432E-8BE7-681DF0503210
P2860
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Plasma exchange and glucocorti ...... a randomized controlled trial
@ast
Plasma exchange and glucocorti ...... a randomized controlled trial
@en
type
label
Plasma exchange and glucocorti ...... a randomized controlled trial
@ast
Plasma exchange and glucocorti ...... a randomized controlled trial
@en
prefLabel
Plasma exchange and glucocorti ...... a randomized controlled trial
@ast
Plasma exchange and glucocorti ...... a randomized controlled trial
@en
P2093
P2860
P356
P1433
P1476
Plasma exchange and glucocorti ...... a randomized controlled trial
@en
P2093
Charles D Pusey
Chen Au Peh
David Jayne
Janak De Zoysa
Jeffrey L Winters
Karen Quillen
Keith Wheatley
Loïc Guillevin
Michael Walsh
Natalie Ives
P2860
P2888
P356
10.1186/1745-6215-14-73
P577
2013-03-14T00:00:00Z
P5875
P6179
1023098364